Tirzepatide for heart failure with preserved ejection fraction and obesity
Packer M, Zile MR, Kramer CM, et al.
N Engl J Med. Pub. online 16 Nov 2024.
Leggi
Finerenone in women and men with heart failure with mildly reduced or preserved ejection fraction: a secondary analysis of the FINEARTS-HF randomized clinical trial
Chimura M, Wang X, Jhund PS, et al.
JAMA Cardiol. 2024:e244613
Leggi
Early adoption of sodium-glucose cotransporter-2 inhibitor in patients hospitalized with heart failure with mildly reduced or preserved ejection fraction
Abdel Jawad M, Spertus JA, Ikeaba U, et al.
JAMA Cardiol. Pub. online 18 Nov 2024.
Leggi
Impact of gestational diabetes mellitus on women’s sexual function: a systematic review and meta-analysis
Maghalian M, Mirghafourvand M
BMC Endocr Disord. 2024;24(1):245.
Leggi
Antidiabetic medication and asthma attacks
Lee B, Man KKC, Wong E, et al.
JAMA Intern Med. Pub. online 18 Nov 2024.
Leggi
Diabetes and obesity: leveraging heterogeneity for precision medicine
Franks PW, Sargent JL
Eur Heart J. 2024:ehae746.
Leggi
The cumulative impact of type 2 diabetes and obstructive sleep apnoea on cardiovascular, liver, diabetes-related and cancer outcomes
Riley DR, Henney A, Anson M, et al.
Diabetes Obes Metab. Pub. online 11 Nov 2024.
Leggi
Finerenone, serum potassium, and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction
Chimura M, Wang X, Jhund PS, et al.
JAMA Cardiol. 2024:e244613.
Leggi
